CEO Rik J. Deitsch reveals Nutra Pharma Corporation’s (NPHC) Value in Interview
In a recent interview (http://dtn.fm/j0AJN) with Stock News Now, the CEO of Nutra Pharma Corporation (OTCQB: NPHC), Rik J. Deitsch, talked about his company’s potential and the value locked in its chest of intellectual property rights. He said that, first and foremost, Nutra Pharma is a bio-technology company, with 21 patents on treatments for myasthenia gravis (MG), juvenile multiple sclerosis (MS), adrenomyeloneuropathy (AMN), human immunodeficiency virus (HIV) and pain. Being a bio-tech company is the “blood… the genetics of the company,” he enthused. As he had explained (http://dtn.fm/hy6Oj) earlier, “Instead of looking at us as a biotech with, potentially, multibillion-dollar…